Clinical Trial Update: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of ABM-1310 in patients with BRAF V600-mutant advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• ABM-1310

Snippet

Sponsor: ABM Therapeutics Shanghai Company Limited | Conditions: Advanced Solid Tumor, BRAF V600 Mutation | Phase 1 | Status: TERMINATED